These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Panitumumab: a review of its use in metastatic colorectal cancer. Keating GM Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659 [TBL] [Abstract][Full Text] [Related]
4. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Battaglin F; Dadduzio V; Bergamo F; Manai C; Schirripa M; Lonardi S; Zagonel V; Loupakis F Expert Opin Biol Ther; 2017 Oct; 17(10):1297-1308. PubMed ID: 28752777 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of panitumumab for K-ras wild-type unresectable or recurrent colorectal cancer - a study focusing on first-line treatment]. Mitomo S; Suto T; Umemura A; Ishida K; Kanno K; Takeda D; Fujita T; Otsuka K; Nitta H; Uesugi N; Sugai T; Wakabayashi G Gan To Kagaku Ryoho; 2014 Jun; 41(6):731-5. PubMed ID: 25129084 [TBL] [Abstract][Full Text] [Related]
7. The safety of monoclonal antibodies for treatment of colorectal cancer. Berger MD; Lenz HJ Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510 [TBL] [Abstract][Full Text] [Related]
8. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858 [TBL] [Abstract][Full Text] [Related]
9. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985 [TBL] [Abstract][Full Text] [Related]
10. [Panitumumab]. Musch A Med Monatsschr Pharm; 2008 Apr; 31(4):122-6. PubMed ID: 18497243 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J; Punt CJ Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Jean GW; Shah SR Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Saif MW; Kaley K; Chu E; Copur MS Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847 [TBL] [Abstract][Full Text] [Related]
15. Integration of panitumumab into the treatment of colorectal cancer. Gravalos C; Cassinello J; García-Alfonso P; Jimeno A Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462 [TBL] [Abstract][Full Text] [Related]
18. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839 [TBL] [Abstract][Full Text] [Related]
19. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Patel DK Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550 [TBL] [Abstract][Full Text] [Related]
20. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]